B
Brent Tetri
Researcher at Saint Louis University
Publications - 10
Citations - 1346
Brent Tetri is an academic researcher from Saint Louis University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 5 publications receiving 982 citations.
Papers
More filters
Journal ArticleDOI
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
TL;DR: The FIB4 index is superior to 7 other non invasive markers of fibrosis in patients with NAFLD; however its performance characteristics highlight the need for even better noninvasive markers.
Journal ArticleDOI
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani,M. Abdelmalek,Guadalupe Garcia-Tsao,Raj Vuppalanchi,Naim Alkhouri,Mary E. Rinella,Mazen Noureddin,Maxmillan Pyko,Mitchell L. Shiffman,Arun J. Sanyal,Adam Allgood,Harold Shlevin,Rex Horton,Eliezer Zomer,William Irish,Zachary Goodman,Stephen A. Harrison,Peter G. Traber,Manal F. Abdelmalek,Luis A. Balart,Brian B. Borg,Michael Charlton,Hari S. Conjeevaram,Michael Fuchs,Reem Ghalib,Pierre M. Gholam,Dina Halegoua-De Marzio,S Harrison,Christopher Jue,Nyingi Kemmer,Kris V. Kowdley,Michelle Lai,Eric Lawitz,Rohit Loomba,Angelo H. Paredes,Don C. Rockey,Miguel Rodriguez,Raymond A. Rubin,Michael P. Ryan,Andrew Scanga,Thomas Sepe,Brent Tetri,Paul J. Thuluvath,Dawn M. Torres,John M. Vierling,Julia Wattacheril,Amanda Weiland,Donald Zogg +47 more
TL;DR: In a phase 2b study of 162 patients with NASH, cirrhosis, and portal hypertension, 1 year of biweekly infusion of belapectin was safe but not associated with significant reduction in HVPG or fibrosis, compared with placebo, however, in a subgroup analysis of patients without esophageal varices, 2 mg/kg bela Expectin did reduce HvPG and development of varices.
Journal ArticleDOI
Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.
Stephen A. Harrison,Elizabeth M. Brunt,Rizwan A. Qazi,Dana Oliver,Brent Tetri,Adrian M. Di Bisceglie,Bruce R. Bacon +6 more
TL;DR: Overall SVR for patients withHCV and significant steatosis or SH is considerably lower than for HCV and Steatosis less than 33% and no SH.
Journal Article
Controversies in the diagnosis and management of NAFLD and NASH
Mary E. Rinella,Rohit Loomba,Stephen H. Caldwell,Kris V. Kowdley,Michael Charlton,Brent Tetri,Stephen A. Harrison,Stephen A. Harrison +7 more
TL;DR: Among patients with biopsy-proven NASH, treatment with pharmacologic agents should be considered; however, the role of specific agents in NASH still needs further study.